Adherium Ltd. · ASX:ADR
Adherium — Investor Conference Call Q1 Fiscal Year 2019
13 slides from Adherium's conference presentation, Oct 31, 2018
Slide 1: Investor Conference Call Q1 Fiscal Year 2019
Investor Conference Call Q1 Fiscal Year 2019 October 31, 2018
Slide 2: Forward Looking Statement
Forward Looking Statement The following material is of a general nature and has only been prepared as a presentation aid. This presentation does NOT contain all of the information that may be required for evaluating Adherium Limited ACN 605 352 510 (Adherium or the Company), its assets, prospects or
Slide 3: Q1 FY 2019 Highlights Summary
Q1 FY 2019 Highlights Summary • Shipped over 4K Hailie sensors, bringing global total sold to date to 135K • Surpassed milestone of acquiring 10 new Hailie subscribers per day • Began patient identification and onboard preparation with Vitalus Health • Expanded potential Enterprise Partner channel r
Slide 4: Market Channel Enterprise Partners
Patient Acquisition Channel • Self-insured corporations • Home health agencies • Pharmacies Business Impact • Covers early adopter portion of the addressable market today • Profitable and scalable customer acquisition model • Demonstrable ROI drives “stickiness” with patients and caregivers • Genera
Slide 5: Market Channel Direct to Consumer (DtC)
Patient Acquisition Channel • Direct, digital marketing • Partnerships • Direct fulfillment Early Traction • Launched eCommerce portals in the U.S. and New Zealand • Built scalable infrastructure for direct delivery to patients • Drove expansion of regulatory (OTC) clearance in the U.S. • Surpassed
Slide 6: Financial Results Review
Financial Results Review Adherium Ltd ©2018 6
Slide 7: Q1 2019 Financial Results
Q1 2019 Financial Results Sequentially from Q4 FY18 to Q1 FY19 3 months to 3 months to Change % on comparable September 30, 2018 June 30, 2018 period basis Revenue $0.5M $2.5M 82% decrease Gross profit $(0.2)M $1.8M 111% decrease -44% margin 81% margin Other income (grants and $19K $208K 91% decreas
Slide 8: First Quarter 2019 Cash Flows
First Quarter 2019 Cash Flows Sequentially from Q4 FY18 to Q1 FY19 3 months to 3 months to Change % September 30, 2018 June 30, 2018 Receipts from customers $1.1M $2.2M 50% decrease Staff costs $3.0M $2.0M 50% increase Other operating cash outflows $2.6M $1.7M 53% increase (net) Total operating cash
Slide 9: Growth Strategies and Outlook
Growth Strategies and Outlook Adherium Ltd ©2018 9
Slide 10: Chronic Respiratory Disease in the U.S.
Chronic Respiratory Disease in the U.S. ASTHMA COPD Patients Diagnosed Chronic or Severe 25M 15M Economic Burden Economic Burden from Non Adherence from Non Adherence $56B+ $50B+ $100B+ Economic Burden of Avoidable Costs in the U.S. from Non-Adherence to Respiratory Medication Adherium Ltd ©2018 10
Slide 11: Growth Opportunities
Growth Opportunities • Extend the reach of platform and grow subscriber base across DtC and Enterprise channels Expansion of DtC & • Broaden the dataset to enhance value (tiered level of subscriptions) Enterprise Partners • Grow addressable market through traditional payors, Medicare/Medicaid, VA, e
Slide 12: Summary and Guidance
Summary and Guidance • Extend the reach of our Hailie platform and grow subscriber base to 20,000 subscribers Grow Subscriptions across our Direct-to-Consumer and Enterprise Partner channels Expand Market • Increase Hailie sensor coverage to 90% of respiratory inhalers on the market • Commence Vital
Slide 13: Thank You
adherium% Adherium THANK YOU
Adherium — Investor Conference Call Q1 Fiscal Year 2019 on 6ix